Ardea Biosciences Inc

Ardea Biosciences — Corporate Update (November 2009)

34 slides from Ardea Biosciences's corporate update, Nov 3, 2009

  1. Slide 1: Company Update November 3, 2009

    Company Update November 3, 2009

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results

  3. Slide 3: Status of Development Programs

    Status of Development Programs RDEA427 RDEA806 900 Series Discovery Preclinical Phase 0/1 Phase 2 A B Phase 3 NNRTI for HIV NNRTI for HIV MEKI for cancer 3 Gout RDEA594 RDEA684 MEKI + sorafenib for cancer RDEA119 Gout Partnered with Bayer RDEA119 3rd Gen NNRTIs

  4. Slide 4: Gout/Hyperuricemia

    Gout/Hyperuricemia Ardea) Biosciences

  5. Slide 5: Hyperuricemia/Gout - Unmet Medical Need

    Hyperuricemia/Gout - Unmet Medical Need Gout is caused by abnormally elevated levels of uric acid (>6.8 mg/dL) Painful and debilitating disease Attacks of severe pain/Inflammation Disfiguring nodules (tophi) Kidney damage (nephropathy) Increasing incidence and severity in U.S. (> 5,000,000 potential

  6. Slide 6: Uric Acid Production and Elimination

    Hare, J. M. et al. Circulation 2003;107:1951-1953 Uric Acid Production and Elimination Allopurinol Febuxostat RDEA594 Probenecid Losartan (Cozaar(r)) Benzbromarone* 6 *Benzbromarone is a URAT1 inhibitor approved outside of the US and later withdrawn due to liver toxicity. Pegloticase URAT1

  7. Slide 7: Selective URAT1 Transporter Inhibition: An Important Contribution to Treatment

    7 Selective URAT1 Transporter Inhibition: An Important Contribution to the Treatment of Hyperuricemia/Gout Inhibition of the URAT1 transporter is a well-validated target for gout Benzbromarone has over 10 million patient-years of treatment experience, with very few side effects, except liver toxicit

  8. Slide 8: Uric Acid-Lowering Was Noticed With RDEA806

    Uric Acid-Lowering Was Noticed With RDEA806 Up to 45% reductions in serum urate (sUA) were observed in healthy volunteers in the 10-day multiple ascending dose study Uric acid reductions of were also observed in all HIV patients in the Phase 2a monotherapy study with RDEA806 A 28-day proof-of-concep

  9. Slide 9: RDEA594 Preclinical and Phase 1 Summary

    RDEA594 Preclinical and Phase 1 Summary RDEA594 is a selective inhibitor of the URAT1 renal transporter (EC50 = 5-10 ^M) without antiviral activity No effect on OAT1 and OAT3 transporters (no interaction with antivirals or other drugs secreted by these transporters) Limited metabolism by CYP450 Inhi

  10. Slide 10: RDEA594 Phase 2a Pilot Pharmacodynamic and Safety Study

    Arm 1:RDEA594 200 mg QD Screening Period Colchicine Treatment Randomize if no gout flare during 2 weeks of colchicine Off drug Off drug Arm 2: Placebo 400 mg QD Off drug Arm 3: Allopurinol 300 mg 5 pts 5 pts 11 pts 7-21 days 1 week 2 weeks total with dose escalation of RDEA594 after Week 1 1 week Po

  11. Slide 11: Phase 2a Cohort Baseline Demographics

    Phase 2a Cohort 1 Baseline Demographics Phase 2a Cohort 1 Baseline Demographics 11

  12. Slide 12: Both Active Arms Produced Significant Reductions in sUA

    (CHART) Randomized Drug Washout Period All Randomized Subjects Excluding Overproducers All Randomized Subjects Excluding Overproducers All Randomized Subjects Excluding Overproducers All Randomized Subjects Excluding Overproducers Response defined as < 6.0 mg/dL Placebo% (n/N) RDEA594% (n/N) Allopur

  13. Slide 13: Allopurinol Results Inconsistent with Previous Studies

    Allopurinol Results From RDEA594 Phase 2a Inconsistent with Previous Studies 13 Allopurinol Arms from Febuxostat Phase 3 Studies Allopurinol Arms from Febuxostat Phase 3 Studies Allopurinol Arms from Febuxostat Phase 3 Studies Allopurinol Arm from RDEA594 Phase 2a Results APEX 28-Week Study FACT 52-

  14. Slide 14: 83% Response in Renally Impaired Patients Observed with RDEA594

    (CHART) 83% Response in Renally Impaired Patients Observed with RDEA594 All Subjects with Mild to Moderate Renal Insufficiency (Cockcroft-Gault) All Subjects with Mild to Moderate Renal Insufficiency (Cockcroft-Gault) All Subjects with Mild to Moderate Renal Insufficiency (Cockcroft-Gault) All Subje

  15. Slide 15: RDEA594 Normalizes Uric Acid Excretion

    RDEA594 Normalizes Uric Acid Excretion (CHART) (CHART) 15

  16. Slide 16: RDEA594 Normalizes Uric Acid Excretion

    (CHART) (CHART) RDEA594 Normalizes Uric Acid Excretion Overall results confirm dose selection for Phase 2b Keeping renal excretion of uric acid at normal levels should minimize risk of stones 16

  17. Slide 17: Adverse Events by Treatment Group

    Treatment Group Mild Moderate Severe SeriousAdverse Event Treatment Group (grade 1) (grade 2) (grade 3) SeriousAdverse Event Treatment Group N Number of Adverse Events (Number of patients, n/N) Number of Adverse Events (Number of patients, n/N) Number of Adverse Events (Number of patients, n/N) Numb

  18. Slide 18: RDEA594 Phase 2 Program Focuses on Important Commercial Opportunities

    RDEA594 Phase 2 Program Focuses on Important Commercial Opportunities Phase 2b monotherapy dose-response, safety and efficacy study (n=140) 3 doses of RDEA594 compared to placebo for 28 days of treatment Supports use in patients who are intolerant to allopurinol, inadequate responders to allopurinol

  19. Slide 19: RDEA594 Phase 2b Monotherapy Dose-Response Study

    RDEA594 Phase 2b Monotherapy Dose- Response, Safety and Efficacy Study - Enrolling 21 days 2 weeks 4 weeks 2 weeks Population: gout patients with hyperuricemia (serum uric acid ^8 mg/dL) total of 140 patients in 4 treatment arms Duration: 8 wks: 2-wk run-in, 4-wk treatment, 2-wk follow-up: dose will

  20. Slide 20: RDEA594 Phase 2b Allopurinol Add-On Combination Study

    RDEA594 Phase 2b Allopurinol Add-On Combination Safety and Efficacy Study - Enrolling Dose Escalation Based on sUA Lowering with 200 mg RDEA594: 18 patients initially, including 12 patients randomized to RDEA594 and 6 patients randomized to placebo 20 RDEA594 100 mg and 300 mg or placebo plus allopu

  21. Slide 21: RDEA594-204: Renal Impairment in Patients with Gout

    RDEA594-204: Renal Impairment in Patients with Gout and Hyperuricemia - Screening Cohort 1A: (6 subjects) 200 mg RDEA594 Subjects must have moderate renal impairment defined as creatinine clearance from (CrCL) ^ 30 mL/min to < 60 mL/min. Subjects will receive RDEA594 once daily for 5 days. Cohorts 1

  22. Slide 22: RDEA594-105: Febuxostat Drug-Drug Interaction and PD Study

    RDEA594-105: Phase 1 Febuxostat Drug-Drug Interaction and PD Study - Ongoing Population: Up to 54 normal healthy volunteers with sUA ^ 6 mg/dL; 18 per panel Males and postmenopausal or sterile women 18 - 65 years of age, inclusive Up to 3 panels with escalating doses of RDEA594 or placebo - 200 mg,

  23. Slide 23: Gout/Hyperuricemia Program Summary

    23 There is a large unmet need for new treatments for gout RDEA594, a selective URAT1 transport inhibitor, corrects the physiologic cause of the vast majority of patients with hyperuricemia: uric acid under- excretion Clinical proof-of-concept has been achieved Phase 2a - Cohort 1 supports the dose

  24. Slide 24: HIV

    HIV Ardea) Biosciences

  25. Slide 25: RDEA427 Has Superior Resistance Profile to Other NNRTIs

    (CHART) RDEA427 Has Superior Resistance Profile to Other NNRTIs 25

  26. Slide 26: Series of NNRTIs Have Excellent Antiviral Profile

    900 Series of NNRTIs Have Excellent Antiviral Profile The 900 series retain potency against a large panel of NNRTI-resistant viruses without the liability of a cyano-vinyl moiety in TMC278 and IDX899 Ardea owns all the IP (CHART) 900 Series 26

  27. Slide 27: Cancer/Inflammation

    Cancer/Inflammation Ardea) Biosciences

  28. Slide 28: The Age of Targeted Cancer Treatments

    The Age of Targeted Cancer Treatments Nexavar MEK Ras Raf c-Myc Herceptin, Erbitux Proliferation Angiogenesis Differentiation Apoptosis cPLA2 PDE4 MNK1/2 Elk-1 MAPKAPK1/3 ARRY-142886 (Ph 2) XL518 (Ph 1) RDEA119 (Ph 1/2) RTK Bcl-2 Mcl-1 c-Jun Tarceva GF ERK2 ERK2 28

  29. Slide 29: RDEA119 is Potent, Highly Specific MEK Inhibitor

    RDEA119 is Potent, Highly Specific MEK Inhibitor Inhibitor Inhibitor >100-fold selectivity in kinase panel of 205 enzymes at 10 µM** *Cell lines: Colo205, A375, A431, HT-29 ** In-house data 1 6 11 16 21 26 31 0 20 40 60 80 100 1 6 11 16 21 26 31 MEK1 & MEK2 MEK1 & MEK2 0 20 40 60 80 100 Ron SRC RDEA

  30. Slide 30: Synergy between RDEA119 and Sorafenib in Hepatoma Cancer Lines

    Synergy between RDEA119 and Sorafenib in Hepatoma Cancer Lines (CHART) (CHART)

  31. Slide 31: RDEA119 Steady-State Plasma Concentrations in Advanced Cancer Patients

    RDEA119 Steady-State Plasma Concentrations in Advanced Cancer Patients 100 mg 60 mg 40 mg 30 mg 20 mg 10 mg 6 mg 4 mg 2 mg Shaded area represents Cmin free drug plasma levels observed in xenograft studies up to 25 mg/kg BID, which produced >100% tumor growth inhibition (TGI) QD Dose 31 Mean RDEA119

  32. Slide 32: Phase 1/2 Advanced Cancer Sorafenib Combination Study

    Study RDEA119-103 Primary Endpoint Safety and tolerability of RDEA119 in combination with sorafenib Secondary Endpoints PK, PD, efficacy Location University of Pennsylvania StudyPopulation Advanced cancer patients, all-comers until DLT reached, then expanded group of patients with specific tumors (r

  33. Slide 33: Financial Position Summary

    Financial Position Summary Statement of Operations(In thousands, except per share data) Six Months EndedJune 30, 2009 RevenueOperating expensesOther income (expense) $ 5,512 27,124 (454) NET LOSS $(22,066) NET LOSS PER SHARE $(1.23) 18.3 million common shares outstanding Expect 2009 year-end cash ba

  34. Slide 34: Near-Term Anticipated Milestones

    Near-Term Anticipated Milestones Near-Term Anticipated Milestones 34

Ardea Biosciences — Corporate Update (November 2009) on 6ix